
Policy & Acquisitions
Mergers & Acquisitions
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Mergers & Acquisitions
Mergers & AcquisitionsEntera Bio Positions EB613 for Phase 3 Osteoporosis StudiesEntera Bio has raised $275 million through an oversubscribed private placement to fully fund Phase 3 registrational studies of EB613, an investigational oral PTH(1-34) therapy for osteoporosis.Fact-Checked
Mergers & AcquisitionsBioMarin, n-Lorem Advance First Mutation-Targeted Therapy for Newly Discovered ReNU SyndromeBioMarin and the n-Lorem Foundation have entered a global collaboration to develop the first investigational antisense oligonucleotide (ASO) therapy for ReNU syndrome.Fact-Checked
Mergers & Acquisitionsargenx Adds First-in-Class FB102 Through $2.2B Forte Biosciences Acquisitionargenx has agreed to acquire Forte Biosciences in a $2.2 billion all-cash deal, adding FB102, a first-in-class anti-CD122 antibody that showed positive Phase 1b results in vitiligo and…Fact-Checked
Mergers & AcquisitionsYarrow Bioscience Initiates Phase 2 Trial of Anti-TSHR Antibody YB-101 for Graves’ Disease and Thyroid Eye Disease Following VYNE MergerYarrow Bioscience has initiated patient dosing in a Phase 2a/2b trial of YB-101, a potential first-in-class anti-TSHR monoclonal antibody for Graves’ disease and thyroid eye disease.Fact-Checked
Mergers & AcquisitionsArcus and Summit Launch Casdatifan–Ivonescimab Trial in Metastatic Kidney CancerArcus Biosciences and Summit Therapeutics launch clinical trial evaluating casdatifan plus ivonescimab for first-line metastatic clear cell renal cell carcinoma.Fact-Checked
Mergers & AcquisitionsHalozyme and Incyte Partner to Advance Subcutaneous INCA033989 for mutCALR-Positive Myeloproliferative NeoplasmsHalozyme Therapeutics has entered a global collaboration and license agreement with Incyte to develop ENHANZE-enabled subcutaneous formulations of the investigational anti-mutCALR antibody INCA033989 for myeloproliferative neoplasms, with the…Fact-Checked
Clinical TrialsBayer Partners with Henry Ford Health to Expand Clinical TrialsBayer and Henry Ford Health have launched a strategic research partnership to expand patient access to clinical trials across cardiovascular and renal diseases, oncology, and women’s health.Fact-Checked
Mergers & AcquisitionsChai Discovery and argenx Partner to Accelerate AI-Driven De Novo Antibody DiscoveryChai Discovery has partnered with argenx to apply its generative AI platform for de novo antibody discovery.Fact-Checked
Mergers & AcquisitionsLilly Acquires AtaiBeckley to Advance BPL-003 for Treatment-Resistant DepressionEli Lilly has agreed to acquire AtaiBeckley in a transaction valued at up to $3.8 billion, strengthening its neuroscience pipeline with BPL-003, an FDA Breakthrough Therapy-designated intranasal 5-MeO-DMT…Fact-Checked
Mergers & AcquisitionsNovartis Partners With Chai Discovery to Advance AI Antibody DiscoveryNovartis has partnered with Chai Discovery to integrate the company’s Chai-3 artificial intelligence platform into therapeutic antibody discovery.Fact-Checked
Mergers & AcquisitionsSpero Secures Global Rights to Innovent’s Anti-CD40L Antibody IBI355 in Up to $1.1B DealSpero Therapeutics has secured worldwide rights outside Greater China to Innovent Biologics’ investigational anti-CD40L antibody IBI355 under a licensing agreement worth up to $1.1 billion.Fact-Checked
Mergers & AcquisitionsAstraZeneca Licenses Zegfrovy from Dizal in Up to $1.5 Billion Deal to Expand EGFR-Mutated Lung Cancer PortfolioAstraZeneca has licensed global rights to Zegfrovy (sunvozertinib) from Dizal in a deal valued at up to $1.5 billion.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.